Ethosuximide

CHEMBL696 Phase 4 معتمد Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

141.2 g/mol

LogP

0.4

Phase

4

This anticonvulsant medication works by blocking a specific type of calcium channel in brain cells that is responsible for the abnormal electrical activity causing absence seizures. It is the drug of choice for absence epilepsy.

الوزن الجزيئي

141,1700 g/mol

LogP

0,40

TPSA

46,20 Å²

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Epilepsy Migraine Breast Cancer Prostate Cancer Colorectal Cancer

آلية العمل

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of …

البنية ثنائية الأبعاد

SVG PNG

Cite this structure

Embed this structure

SMILES

CCC1(C)CC(=O)NC1=O

InChI

InChI=1S/C7H11NO2/c1-3-7(2)4-5(9)8-6(7)10/h3-4H2,1-2H3,(H,8,9,10)

Molecular Formula

C7H11NO2

HBD / HBA

1 / 2

الروابط القابلة للدوران

1

الذرات الثقيلة

10

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

This anticonvulsant medication works by blocking a specific type of calcium channel in brain cells that is responsible for the abnormal electrical activity causing absence seizures. It is the drug of choice for absence epilepsy.

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.

Yes, Ethosuximide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL696. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3291. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

هل تبحث عن معلومات ملائمة للمرضى؟

Ethosuximide على PillFYI

البنية

بيانات سريعة

الصيغة الجزيئية: C7H11NO2
المرادفات: 1

روابط خارجية

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.